Clairity is broadening U.S. availability of its Clairity Breast AI-based breast cancer risk assessment platform through a partnership with consumer health testing company Everlywell.
Clairity Breast analyzes a single routine screening mammogram to predict a woman's five-year risk of developing breast cancer. The platform received De Novo authorization from the U.S. Food and Drug Administration (FDA) in 2025. It was previously available only at Beth Israel Deaconess Medical Center in Massachusetts and Invision Sally Jobe Imaging Center in Colorado.
Patients in the U.S. with a qualifying recent screening mammogram can now access the assessment through Everlywell's consumer platform, which includes physician order review, digital results delivery, and clinician-supported follow-up, Clairity said. The company was founded by breast imaging researcher Connie Lehman, MD, PhD.
